anyone having trouble taking aromatase inhibitors?

[Hopeful]

Terri,

The link to the abstract about autoimmune disease and AI arthralgia was from the 2008 ASCO. Apparently, they do not archive abstracts from prior meetings on their website once the current meeting abstracts are added to the site. If I can locate another source for it, I will link it for you, but at the moment I am not sure where else to look for it.

Hopeful

[TSund]

Thanks Hopeful!

[Laurel]

I read somewhere that the aches and pains associated with both Tamoxifen and A.I.'s is lessened by taking large doses of Vit D. I take 2500 U daily with Calcium and I haven't had any serious stiffness with my Tamoxifen. I am hoping I will tolerate A.I.s as well when I switch over in another year.

[Rich66]

1: Crit Rev Oncol Hematol. 2009 Apr 13. [Epub ahead of print] Links
Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials.

Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G.
Department of Medical Oncology, University General Hospital of Heraklion, Greece.
PURPOSE: To compare efficacy and tolerability of fulvestrant with aromatase inhibitors and tamoxifen that actually represent the standard of care in hormone-sensitive breast cancer. METHODS: Systematic review and meta-analysis of available trials. Primary outcomes were overall survival, time to progression, clinical outcome and objective response. Secondary outcome was the tolerability profile of the drugs. RESULTS: Four trials were identified with 2125 eligible patients. There was no statistically significant difference between fulvestrant and other hormonal agents in terms of overall survival (pooled HR: 1.047, 95% CI: 0.688-1.592), time to progression (pooled HR: 0.994, 95% CI: 0.691-1.431), clinical benefit (pooled OR: 1.044, 95% CI: 0.828-1.315) or objective response rate (pooled OR: 0.949, 95% CI: 0.736-1.224). A higher incidence of joint disorders (pooled OR: 0.621, 95% CI: 0.424-0.909; P=0.014) was noted in patients receiving hormonal agents other than fulvestrant. CONCLUSION: Fulvestrant was similar to other hormonal agents with respect to efficacy measures, with good tolerability profile.